160 research outputs found

    On the Nature of the X-ray Emission from the Ultraluminous X-ray Source, M33 X-8: New Constraints from NuSTAR and XMM-Newton

    Full text link
    We present nearly simultaneous NuSTAR and XMM-Newton observations of the nearby (832 kpc) ultraluminous X-ray source (ULX) M33 X-8. M33 X-8 has a 0.3-10 keV luminosity of LX ~ 1.4 x 10^39 erg/s, near the boundary of the "ultraluminous" classification, making it an important source for understanding the link between typical Galactic X-ray binaries and ULXs. Past studies have shown that the 0.3-10 keV spectrum of X-8 can be characterized using an advection-dominated accretion disk model. We find that when fitting to our NuSTAR and XMM-Newton observations, an additional high-energy (>10 keV) Comptonization component is required, which allows us to rule out single advection-dominated disk and classical sub-Eddington models. With our new constraints, we analyze XMM-Newton data taken over the last 17 years to show that small (~30%) variations in the 0.3-10 keV flux of M33 X-8 result in spectral changes similar to those observed for other ULXs. The two most likely phenomenological scenarios suggested by the data are degenerate in terms of constraining the nature of the accreting compact object (i.e., black hole versus neutron star). We further present a search for pulsations using our suite of data; however, no clear pulsations are detected. Future observations designed to observe M33 X-8 at different flux levels across the full 0.3-30 keV range would significantly improve our constraints on the nature of this important source.Comment: Accepted for publication in ApJ (15 pages, 4 tables, 6 figures

    Characterization of MgAlâ‚‚Oâ‚„ Sintered Ceramics

    Get PDF
    Single phase MgAl2O4 was made from a one-to-one molar ratio of MgO and Al2O3 powders mixed using ball-milling. Mixtures of MgO and Al2O3 were subsequently treated in planetary ball mill for 30, 60, 90 and 120 minutes in air. The aim of this study was to examine phase composition, microstructure, and densification behavior of sintered specimens. After sintering in dilatometer at 1500 °C, the powder was converted to single phase MgAl2O4. The results show that mechanical activation improved the densification behavior of MgAl2O4 sintered specimens, and it reduced the onset temperature for sintering by approx. 100°C. Based on dilatometer data, powders were subsequently densified at 1450°C by hot pressing. Almost all specimens exhibited full density, while sample activated for 30 minutes showed the fastest densification rate

    Astro 2020 Science White Paper: Time Domain Studies of Neutron Star and Black Hole Populations: X-ray Identification of Compact Object Types

    Get PDF
    What are the most important conditions and processes governing the growth of stellar-origin compact objects? The identification of compact object type as either black hole (BH) or neutron star (NS) is fundamental to understanding their formation and evolution. To date, time-domain determination of compact object type remains a relatively untapped tool. Measurement of orbital periods, pulsations, and bursts will lead to a revolution in the study of the demographics of NS and BH populations, linking source phenomena to accretion and galaxy parameters (e.g., star formation, metallicity). To perform these measurements over sufficient parameter space, a combination of a wide-field (>5000 deg^2) transient X-ray monitor over a dynamic energy range (~1-100 keV) and an X-ray telescope for deep surveys with <5 arcsec PSF half-energy width (HEW) angular resolution are required. Synergy with multiwavelength data for characterizing the underlying stellar population will transform our understanding of the time domain properties of transient sources, helping to explain details of supernova explosions and gravitational wave event rates.Comment: 9 pages, 2 figures. Submitted to the Astro2020 Decadal Surve

    Black Holes and Neutron Stars in Nearby Galaxies: Insights from NuSTAR

    Get PDF
    Nearby galaxy surveys have long classified X-ray binaries (XRBs) by the mass category of their donor stars (high-mass and low-mass). The NuSTAR observatory, which provides imaging data at E >10>10 keV, has enabled the classification of extragalactic XRBs by their compact object type: neutron star (NS) or black hole (BH). We analyzed NuSTAR/Chandra/XMM-Newton observations from a NuSTAR-selected sample of 12 galaxies within 5 Mpc having stellar masses (M⋆M_{\star}) 107−1110^{7-11} M⊙M_{\odot} and star formation rates (SFR) ≈0.01−15\approx0.01-15 M⊙M_{\odot} yr−1^{-1}. We detect 128 NuSTAR sources to a sensitivity of ≈1038\approx10^{38} erg s−1^{-1}. Using NuSTAR color-intensity and color-color diagrams we classify 43 of these sources as candidate NS and 47 as candidate BH. We further subdivide BH by accretion states (soft, intermediate, and hard) and NS by weak (Z/Atoll) and strong (accreting pulsar) magnetic field. Using 8 normal (Milky Way-type) galaxies in the sample, we confirm the relation between SFR and galaxy X-ray point source luminosity in the 4-25 and 12-25 keV energy bands. We also constrain galaxy X-ray point source luminosity using the relation LX=αM⋆+βSFRL_{\rm{X}}=\alpha M_{\star}+\beta\text{SFR}, finding agreement with previous work. The XLF of all sources in the 4-25 and 12-25 keV energy bands matches with the α=1.6\alpha=1.6 slope for high-mass XRBs. We find that NS XLFs suggest a decline beginning at the Eddington limit for a 1.4 M⊙M_{\odot} NS, whereas the BH fraction shows an approximate monotonic increase in the 4-25 and 12-25keV energy bands. We calculate the overall ratio of BH to NS to be ≈1\approx1 for 4-25 keV and ≈2\approx2 for 12-25 keV.Comment: 38 pages, 12 figures, 8 tables. ApJ, in pres

    Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide

    Get PDF
    Recent studies have suggested that plasma-derived proteins may be potential biomarkers relevant for graft-versus-host disease and/or non-relapse mortality occurring after allogeneic blood or marrow transplantation. However, none of these putative biomarkers have been assessed in patients treated either with human leukocyte antigen-haploidentical blood or marrow transplantation or with post-transplantation cyclophosphamide, which has been repeatedly associated with low rates of severe acute graft-versus-host disease, chronic graft-versus-host disease, and non-relapse mortality. We explored whether seven of these plasma-derived proteins, as measured by enzyme-linked immunosorbent assays, were predictive of clinical outcomes in post-transplantation cyclophosphamide-treated patients using plasma samples collected at serial predetermined timepoints from patients treated on prospective clinical studies of human leukocyte antigen-haploidentical (n=58; clinicaltrials.gov Identifier: 00796562) or human leukocyte antigen-matched-related or -unrelated (n=100; clinicaltrials.gov Identifiers: 00134017 and 00809276) T-cell-replete bone marrow transplantation. Day 30 levels of interleukin-2 receptor α, tumor necrosis factor receptor 1, serum STimulation-2 (IL1RL1 gene product), and regenerating islet-derived 3-α all had high areas under the curve of 0.74–0.97 for predicting non-relapse mortality occurrence by 3 months post-transplant in both the human leukocyte antigen-matched and human leukocyte antigen-haploidentical cohorts. In both cohorts, all four of these proteins were also predictive of subsequent non-relapse mortality occurring by 6, 9, or 12 months post-transplant and were significantly associated with non-relapse mortality in univariable analyses. Furthermore, day 30 elevations of interleukin-2 receptor α were associated with grade II–IV and III–IV acute graft-versus-host disease occurring after day 30 in both cohorts. These data confirm that plasma-derived proteins previously assessed in other transplantation platforms appear to retain prognostic and predictive utility in patients treated with post-transplantation cyclophosphamide

    Developments in Capture- γ Libraries for Nonproliferation Applications

    Get PDF
    The neutron-capture reaction is fundamental for identifying and analyzing the γ-ray spectrum from an unknown assembly because it provides unambiguous information on the neutron-absorbing isotopes. Nondestructive-assay applications may exploit this phenomenon passively, for example, in the presence of spontaneous-fission neutrons, or actively where an external neutron source is used as a probe. There are known gaps in the Evaluated Nuclear Data File libraries corresponding to neutron-capture γ-ray data that otherwise limit transport-modeling applications. In this work, we describe how new thermal neutron-capture data are being used to improve information in the neutron-data libraries for isotopes relevant to nonproliferation applications. We address this problem by providing new experimentally-deduced partial and total neutron-capture reaction cross sections and then evaluate these data by comparison with statistical-model calculations

    Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology

    Get PDF
    Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18–80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 European countries 2012–2013. The patients were interviewed and investigated in order to enable a comparison between their actual risk factor control with that recommended in current European management guidelines and the outcome in previously conducted surveys. Results: A total of 2846 (46%) patients had no diabetes, 1158 (19%) newly diagnosed diabetes and 2183 (35 %) previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60%, respectively. A blood pressure target of 9.0% (>75 mmol/mol). Of the patients with diabetes 69% reported on low physical activity. The proportion of patients participating in cardiac rehabilitation programmes was low (≈40%) and only 27% of those with diabetes had attended diabetes schools. Compared with data from previous surveys the use of cardioprotective drugs had increased and more patients were achieving the risk factor treatment targets. Conclusions: Despite advances in patient management there is further potential to improve both the detection and management of patients with diabetes and coronary artery disease

    Tunable Growth Factor Delivery from Injectable Hydrogels for Tissue Engineering

    Get PDF
    Current sustained delivery strategies of protein therapeutics are limited by the fragility of the protein, resulting in minimal quantities of bioactive protein delivered. In order to achieve prolonged release of bioactive protein, an affinity-based approach was designed which exploits the specific binding of the Src homology 3 (SH3) domain with short proline-rich peptides. Specifically, methyl cellulose was modified with SH3-binding peptides (MC-peptide) with either a weak affinity or strong affinity for SH3. The release profile of SH3-rhFGF2 fusion protein from hyaluronan MC-SH3 peptide (HAMC-peptide) hydrogels was investigated and compared to unmodified controls. SH3-rhFGF2 release from HAMC-peptide was extended to 10 days using peptides with different binding affinities compared to the 48 h release from unmodified HAMC. This system is capable of delivering additional proteins with tunable rates of release, while maintaining bioactivity, and thus is broadly applicable
    • …
    corecore